Literature DB >> 9640540

The nuclear receptor ligand-binding domain: structure and function.

D Moras1, H Gronemeyer.   

Abstract

In the past few years our understanding of nuclear receptor action has dramatically improved as a result of the elucidation of the crystal structures of the empty (apo) ligand-binding domains of the nuclear receptor and of complexes formed by the nuclear receptor's ligand-binding domain bound to agonists and antagonists. Furthermore, the concomitant identification and functional analysis of co-regulators (transcriptional intermediary factors [TIFs], comprising co-activators and co-repressors) previously predicted from squelching studies, have deepened this understanding. Recent data have provided the structural basis for the specific recognition of ligands and the molecular mechanisms of agonism and antagonism, enabling us to gain a comprehensive view of the early steps of nuclear receptor action.

Mesh:

Substances:

Year:  1998        PMID: 9640540     DOI: 10.1016/s0955-0674(98)80015-x

Source DB:  PubMed          Journal:  Curr Opin Cell Biol        ISSN: 0955-0674            Impact factor:   8.382


  170 in total

1.  Large-scale expression and purification of the human vitamin D receptor and its ligand-binding domain for structural studies.

Authors:  K Juntunen; N Rochel; D Moras; P Vihko
Journal:  Biochem J       Date:  1999-12-01       Impact factor: 3.857

2.  Rational discovery of novel nuclear hormone receptor antagonists.

Authors:  M Schapira; B M Raaka; H H Samuels; R Abagyan
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

3.  Enantiomer discrimination illustrated by high-resolution crystal structures of the human nuclear receptor hRARgamma.

Authors:  B P Klaholz; A Mitschler; M Belema; C Zusi; D Moras
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

4.  Ligand-dependent degradation of retinoid X receptors does not require transcriptional activity or coactivator interactions.

Authors:  D L Osburn; G Shao; H M Seidel; I G Schulman
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

5.  Crystal structure of the human RXRalpha ligand-binding domain bound to its natural ligand: 9-cis retinoic acid.

Authors:  P F Egea; A Mitschler; N Rochel; M Ruff; P Chambon; D Moras
Journal:  EMBO J       Date:  2000-06-01       Impact factor: 11.598

6.  FHL2, a novel tissue-specific coactivator of the androgen receptor.

Authors:  J M Müller; U Isele; E Metzger; A Rempel; M Moser; A Pscherer; T Breyer; C Holubarsch; R Buettner; R Schüle
Journal:  EMBO J       Date:  2000-02-01       Impact factor: 11.598

7.  Phosphorylation by p38MAPK and recruitment of SUG-1 are required for RA-induced RAR gamma degradation and transactivation.

Authors:  Maurizio Giannì; Annie Bauer; Enrico Garattini; Pierre Chambon; Cécile Rochette-Egly
Journal:  EMBO J       Date:  2002-07-15       Impact factor: 11.598

8.  Folding and stability of the ligand-binding domain of the glucocorticoid receptor.

Authors:  Stephen H McLaughlin; Sophie E Jackson
Journal:  Protein Sci       Date:  2002-08       Impact factor: 6.725

9.  Dynamic nature of transcriptional regulation of nuclear receptor target genes in the context of chromatin organization.

Authors:  Sami Väisänen; Juha Matilainen; Carsten Carlberg
Journal:  Dermatoendocrinol       Date:  2011-07-01

10.  A canonical cation-π interaction stabilizes the agonist conformation of estrogen-like nuclear receptors.

Authors:  Núria Queralt-Rosinach; Jordi Mestres
Journal:  Eur Biophys J       Date:  2010-04-03       Impact factor: 1.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.